Trastuzumab deruxtecan Clinical Trials
31 recruitingDrug
Phase 218Phase 15Phase 34Phase 41
Showing 1–20 of 31 trials
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled293 locationsNCT06764875
Recruiting
Phase 3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Breast Neoplasms
Merck Sharp & Dohme LLC1,000 enrolled183 locationsNCT07060807
Recruiting
Phase 3
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Biliary Tract Cancer
AstraZeneca620 enrolled270 locationsNCT06467357
Recruiting
Phase 2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Gastric Cancer
AstraZeneca450 enrolled100 locationsNCT04379596
Recruiting
Phase 2
NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer
HER2 Positive Early Breast Cancer
West German Study Group702 enrolled44 locationsNCT05704829
Recruiting
Phase 1
Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors
Advanced Solid TumorMetastatic Solid TumorSolid Tumor
Lei Zheng57 enrolled1 locationNCT07086768
Recruiting
DESTINY-PANTUMOUR04
Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled17 locationsNCT07124000
Recruiting
Phase 1Phase 2
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Metastatic Breast CancerColorectal, CancerEsophageal Adenocarcinoma+2 more
Boehringer Ingelheim768 enrolled108 locationsNCT06324357
Recruiting
Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response
Breast CancerMetastatic Breast CancerDrug-Related Side Effects and Adverse Reactions+1 more
Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental70 enrolled1 locationNCT07582887
Recruiting
Phase 3
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Endometrial Cancer
AstraZeneca600 enrolled250 locationsNCT06989112
Recruiting
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)
HER2-positive Advanced Gastric CancerHER2-positive Gastroesophageal Junction Adenocarcinoma
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company257 enrolled76 locationsNCT05993234
Recruiting
Phase 2
Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)
Colorectal, CancerResectable Colorectal Carcinoma
Gruppo Oncologico del Nord-Ovest197 enrolled1 locationNCT05845450
Recruiting
Phase 2
Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer
Metastatic CancerLeptomeningeal MetastasisBrain Cancer+2 more
Memorial Sloan Kettering Cancer Center30 enrolled1 locationNCT06058988
Recruiting
DESTINY Breast Respond HER2-low Europe
Metastatic Breast CancerUnresectable Breast CancerHER2-low Expressing Breast Cancer
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company1,155 enrolled211 locationsNCT05945732
Recruiting
Phase 2
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal CancerPart 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal Cancer
AstraZeneca468 enrolled123 locationsNCT04482309
Recruiting
A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)
Breast CancerHER2-low Breast CancerHER2-positive Breast Cancer+1 more
Daiichi Sankyo800 enrolled54 locationsNCT06210776
Recruiting
Phase 2
Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer
Stomach Neoplasms
Jeeyun Lee50 enrolled1 locationNCT06630130
Recruiting
Phase 1Phase 2
Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric Cancer
Stomach Neoplasm
Jeeyun Lee61 enrolled1 locationNCT06085755
Recruiting
Phase 2
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute15 enrolled1 locationNCT06409390
Recruiting
Phase 2
Basket Study for Oligo-metastatic Breast Cancer
HER2-positive Breast Cancer
The Netherlands Cancer Institute72 enrolled1 locationNCT05982678